These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27979595)

  • 1. Imidazopyridyl compounds as aldosterone synthase inhibitors.
    Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
    Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
    J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
    Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
    J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
    Hoyt SB; Taylor J; London C; Ali A; Ujjainwalla F; Tata J; Struthers M; Cully D; Wisniewski T; Ren N; Bopp C; Sok A; Verras A; McMasters D; Chen Q; Tung E; Tang W; Salituro G; Clemas J; Zhou G; MacNeil D; Duffy R; Xiong Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2384-2388. PubMed ID: 28416132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of targeting CYP11B.
    Bernhardt R
    Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
    Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
    J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
    Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2).
    Martin RE; Lehmann J; Alzieu T; Lenz M; Carnero Corrales MA; Aebi JD; Märki HP; Kuhn B; Amrein K; Mayweg AV; Britton R
    Org Biomol Chem; 2016 Jul; 14(25):5922-7. PubMed ID: 27245438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
    Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
    Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
    J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.